Nexdius Pty Ltd and Minister for Health

Link copied
Case Copied 27 min read

Nexdius Pty Ltd and Minister for Health [2017] AATA 2295 (21 November 2017)

Division:GENERAL DIVISION

File Number(s):      2016/2163

Re:Nexdius Pty Ltd

APPLICANT

AndMinister for Health

RESPONDENT

DECISION

Tribunal:Deputy President J W Constance

Senior Member A Poljak

Date:21 November 2017

Place:Sydney

The decision under review is affirmed.

..................................[sgd]...................................

J W Constance
Deputy President

CATCHWORDS

HEALTH – Therapeutic Goods – Advertisement – approval of television advertisement – therapeutic goods advertising code – characteristics of the reasonable person – claims, statements and comparisons – whether advertisement complies with clause 4 of the advertising code – unwarranted and unrealistic expectations – product effectiveness – correct and balanced statements – claims and statements verified by sponsor – abuse of trust or exploiting the lack of knowledge of consumers – whether language used could bring about fear or distress – Comparative advertisements – must not be misleading or likely to be misleading – public health messages – sunscreens – solar UV radiation – UVB – production of vitamin D – sunburn – decision affirmed

LEGISLATION

Therapeutic Goods Act 1989(Cth) s 42C

CASES

Cadbury Schweppes Pty Ltd v Darrell Lea Chocolate Shops Pty Ltd (2007) 159 FCR 397

SECONDARY MATERIALS

Therapeutic Goods Advertising Code 2015 (Cth)

Therapeutic Goods Regulations 1990 (Cth) reg 5G, 5M

REASONS FOR DECISION

Deputy President J W Constance
Senior Member A Poljak

21 November 2017

INTRODUCTION

  1. Nexdius Pty Ltd (“Nexdius”), the applicant, sought to advertise three “Solar D” branded sunscreens; Solar D Daily Use SPF 50 (AUST L 224353); Solar D Active SPF 30 (AUST L 2243554); and Solar D Kids (AUST L 2243555) (“Solar D sunscreens” and “Solar D”). Nexdius is the sponsor of the Solar D sunscreens which are listed in the Australian Register of Therapeutic Goods (“ARTG”).

  2. These proceedings concern certain claims and comparisons made and conveyed by an advertisement for the three Solar D sunscreens (“the Advertisement”). Nexdius asserts that the distinctive claim of Solar D sunscreens is that they provide a high level of broad-spectrum protection, including against sunburn, while allowing some of the sunlight through that users need to produce vitamin D.

  3. On 31 March 2016, a delegate of the Minister for Health (“Minister”), pursuant to regulation 5M of the Therapeutic Goods Regulations 1990 (Cth) (“the Regulations”), decided to affirm the decision made on 8 September 2015, refusing to approve the Advertisement (the “decision”). The reason for the decision was that the Advertisement did not comply with reg. 5G(1)(a) of the Regulations in that, when assessed in terms of its probable impact on the reasonable person to whom it was directed, it did not comply with clauses 4(1)(b), 4(2)(a), (2)(d), (2)(e)(ii) and 4(5) of the Therapeutic Goods Advertising Code 2015 (Cth) (“the Code”).

  4. The issues to be determined in these proceedings are:

    (a)the characteristics of the reasonable person to whom the Advertisement is directed (clause 3(2) of the Code);

    (b)what claims, statements and comparisons…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Nexdius Pty Ltd and Minister for Health and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2017] AATA 2295
Decision Date

CaseChat Overview and Summary

The Administrative Appeals Tribunal considered an appeal by Nexdius Pty Ltd against a decision by the Minister for Health to refuse approval for a television advertisement for a sunscreen product. The dispute centred on whether the advertisement complied with the Therapeutic Goods Advertising Code, specifically concerning claims made about the product's ability to allow for vitamin D production.

The Tribunal was required to determine whether the advertisement made correct and balanced statements, whether claims were verified by the sponsor, and whether the language used could exploit consumer trust or knowledge. A key issue was whether the advertisement's claim that the sunscreen allowed users to obtain sunlight necessary for vitamin D production was substantiated and presented in a way that did not mislead consumers.

The Tribunal found that while some scientific data suggests that limited sun exposure can facilitate vitamin D production, the advertisement's claim was not sufficiently balanced or verified in the context of the Therapeutic Goods Advertising Code. Although expert evidence indicated that the product allowed for increased UVB transmittance compared to other sunscreens, and that this could be physiologically significant for vitamin D production, the Tribunal concluded that the advertisement did not meet the requirements of clause 4(5) of the Code. Consequently, the Tribunal affirmed the decision to refuse approval for the advertisement.

Background

Background to the litigation

Nexdius Pty Ltd, a company involved in the formulation and sale of sunscreen products, including Solar D, sought approval from the relevant Australian health authorities for a television advertisement promoting its sunscreen. The primary focus of the advertisement was the claim that Solar D allows users to get some of the sunlight necessary for the human body to produce vitamin D while still protecting the skin from harmful solar ultraviolet radiation (UVR). The Minister for Health refused to approve the advertisement, leading to Nexdius challenging this decision in court. The case centred on whether the advertisement complied with the Therapeutic Goods Advertising Code and the relevant regulations.

The crux of the dispute lay in the advertisement's claim regarding vitamin D production. Nexdius argued that the advertisement was truthful, stating that Solar D permits some UVB rays to pass through, thereby enabling the production of vitamin D. They supported this claim with evidence from Professor Holick and Professor Mason, both experts in the field of vitamin D and UVB exposure, who testified that an increase in UVB transmittance can proportionally increase cutaneous vitamin D production, especially with significant skin exposure. Additionally, a Therapeutic Goods Administration (TGA) laboratory test comparing Solar D with other sunscreens indicated that Solar D allowed more UVB transmission compared to the comparator products.

Despite the evidence presented by Nexdius, the court needed to determine if the advertisement, by making certain claims about Solar D's effect on vitamin D production, was misleading or likely to mislead the public. The court examined whether the advertisement provided correct and balanced statements verified by the sponsor and whether it exploited the lack of knowledge of consumers or brought about fear or distress. The court also scrutinised whether the advertisement complied with clause 4 of the advertising code, which mandates that advertisements must not create unwarranted or unrealistic expectations about the product's effectiveness. The court's decision affirmed the Minister for Health's refusal to approve the advertisement, finding that it did not comply with the relevant regulatory requirements.

This case originated as an application for review by Nexdius Pty Ltd against a decision made by the Minister for Health to refuse approval for a television advertisement for the product Solar D sunscreen. The matter came before the Administrative Appeals Tribunal (AAT) in an appeal from the original decision made by the Department of Health. The AAT's role was to review the decision under the Administrative Appeals Tribunal Act 1975 and to determine whether the decision was legally sound and whether it was based on relevant considerations. Key procedural steps included the filing of the application for review, the subsequent hearing where evidence and submissions were presented, and expert testimonies were examined, particularly from Professor Holick and Professor Mason. The Tribunal reviewed the Therapeutic Goods Advertising Code and assessed the advertisement's compliance with clause 4, focusing on whether it made correct and balanced statements that were verified by the sponsor. The Tribunal's decision affirmed the Minister's decision, concluding that the advertisement did not comply with the Code and thus approval must be refused.

Decision

Reasons for decision

Accordingly, we are satisfied that the Advertisement does not comply with clause 4(5) of the Code.DECISION Regulation 5G(3) requires that an advertisement must be refused if any matter in sub- regulation 5G(1) is not satisfied. As compliance with the Code is a matter in reg. 5G(1)(a), and compliance with the Code is not satisfied in this case, under reg. 5G(3), approval of the Advertisement must be refused. The decision under review is affirmed.

Ratio Decidendi

Legal Principle Established

Some data indicates that people will achieve a sufficient vitamin D status (greater than 50nmol/L) if, in those days when there is some UVB, they expose approximately 15% of body surface (that is arms and hands or equivalent areas of skin), around the middle of the day, to one third of the amount of sun exposure that would just cause slight reddening of the skin. This amount of sunlight exposure depends on skin colour, latitude and time of year and time of day, but for people with mostly white skin, in summer in Australia, this equates to approximately 6 to 10 minutes, mid-morning or mid-afternoon.CONSIDERATIONDoes the Advertisement Comply with Clause 4 of the Code: Reg. 5G(1) of the Regulations?Clause 4(1)(b): Correct and balanced statements only and claims verified by the sponsor Sunscreen use, transmission of sunlight and vitamin D production The distinctive claim of Solar D is that it allows users to get some of the sunlight human bodies need to produce vitamin D. For the following reasons, we are satisfied that this claim is a correct and balanced statement and is verified by Nexdius. Professor Holick opined in his report dated 20 October 2016, that in regards to the results contained in the TGA Laboratory Report, “the increased UVB transmittance observed for the Solar D products versus the tested comparators can certainly be physiologically significant in relation to cutaneous vitamin D production, particularly in the context of sunscreen use over large exposure areas and over time (e.g. people wearing minimal clothing or swimwear at the beach)” (at [39]). He goes on to say that “…cutaneous vitamin D production occurs linearly relative to UVB exposure until equilibrium is reached. Therefore, even a small increase in UVB transmittance will result in a proportional increase in cutaneous vitamin D production, and if a large area of skin is exposed, then the cumulative dose of vitamin D produced may be substantial” (at [40]). At hearing, Professor Mason accepted that broad-spectrum sunscreens in Australia are designed to, and do, impede the transmission of UVB such that with the use of sunscreen (if applied correctly) vitamin D synthesis would be lower than it would otherwise be. She accepted the proposition that an increased exposure to UVB reception, will generally lead to an increase in vitamin D production, so long as the people being exposed are not hitting their threshold limit. Specifically in regards to Solar D, Professor Mason agreed that it lets more UVB through. A Therapeutic Goods Administration (“TGA”) laboratory test was conducted comparing two of Nexdius’ sunscreens (one of which is the subject of these proceedings) to a Nivea brand SPF 15 product and a Cancer Council brand SPF 30+ product (“the TGA Tests”). Three test methods were used to measure UV transmittance of each of the four sunscreens: a solution test method at two different concentrations of test product (0.8mg/mL and 0.4mg/mL), and a thin film method. The methodology, results and conclusions of the TGA Tests are set out in a report dated 24 November 2015 (“TGA Laboratory Report”).